These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34127645)

  • 1. Efficacy of green jackfruit flour as a medical nutrition therapy replacing rice or wheat in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
    Rao AG; Naik KS; Unnikrishnan AG; Joseph J
    Nutr Diabetes; 2021 Jun; 11(1):18. PubMed ID: 34127645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
    Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose.
    Kasthuri S; Poongothai S; Anjana RM; Selvakumar J; Muthukumar S; Kayalvizhi S; Tariq S; Honey E; Gupta PK; Venkatesan U; Mohan V
    Diabetes Technol Ther; 2021 Mar; 23(3):213-220. PubMed ID: 32916063
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.
    Yamada Y; Terauchi Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
    Adv Ther; 2018 Mar; 35(3):367-381. PubMed ID: 29488152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J; Samols E; Muchmore DB; Schneider J
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
    Seino Y; Sasaki T; Fukatsu A; Sakai S; Samukawa Y
    Curr Med Res Opin; 2014 Jul; 30(7):1219-30. PubMed ID: 24597840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
    Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
    J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
    Kadowaki T; Haneda M; Inagaki N; Terauchi Y; Taniguchi A; Koiwai K; Rattunde H; Woerle HJ; Broedl UC
    Adv Ther; 2014 Jun; 31(6):621-38. PubMed ID: 24958326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.